The Gel That Became a Business

Some cancers announce themselves with drama. Low-grade bladder cancer does the opposite. It is usually slow-growing and rarely life-threatening, which is the good news.

The hard part is that it tends to return. A patient has a tumor removed in a short operation under anesthesia. Months later, a follow-up camera exam finds another one, and then another procedure follows. For many people, that cycle continues for years.

Anyone who has watched a relative go through it knows the weariness. The medical risk is modest, but the burden of surveillance and repeat procedures is not.

That cycle is the opening UroGen Pharma (NASDAQ:URGN) saw. The company, listed on Nasdaq under the ticker URGN, sells treatments for cancers of the urinary tract. Its core idea is a better way to deliver an old drug.

The product: an old medicine in a clever package

The drug is mitomycin, a decades-old chemotherapy that is cheap and well understood. The problem was never the medicine. It was keeping it in contact with the bladder wall long enough to work, since the body flushes liquids out within hours.

UroGen mixes mitomycin into a gel that is liquid when cold and thickens at body temperature. It coats the bladder lining and releases the drug slowly over hours. The product is called ZUSDURI, approved by the FDA (the U.S. Food and Drug Administration) in 2025.

The results are encouraging. In the pivotal trials, roughly 72% of patients were still free of disease at 24 months. For a condition defined by recurrence, that is meaningful.

For the business, there is a second benefit. The treatment can be given in a urologist's own office, where about 70% of eligible patients are seen, instead of in a hospital operating room.

The launch: The part that actually worked

Biotech launches usually disappoint. Hospitals are slow, billing is tangled, and doctors are creatures of habit.

This one has worked. In the quarter just reported, UroGen's total revenue was $89.0 million, up from $27.5 million a year earlier. ZUSDURI alone brought in $68.0 million, up 35% from the prior quarter. Just a year ago it earned $1.8 million.

The company's loss shrank to match. The net loss was $1.5 million, compared with $33.3 million a year earlier. Management says it expects to turn a profit in the fourth quarter.

The most telling data is about doctors. Unique prescribers rose from 452 to 662 in a quarter, and repeat prescribers rose from 204 to 331, about half of the total.

That repeat figure matters because a doctor who tries a drug once is curious. A doctor who orders it again has decided it works in their practice.

One more detail: The number of active sites of care rose only modestly, from 1,444 to 1,538. Most of the growth comes from existing offices using it more, not from new offices signing on. That tends to be the sturdier kind of growth.

There was one operational change that helped. A permanent billing code, called a J-code (a unique identifier that tells insurers exactly which drug was administered), took effect on Jan. 1, 2026. Before it, urologists faced reimbursement friction. Now claims flow more smoothly.

The first complication: The older product is shrinking

UroGen's earlier product, JELMYTO, treats a rarer cancer of the upper urinary tract. It was the company's bread and butter. Management had hoped the new launch would pull it along, a so-called halo effect, where success with one product lifts its sibling.

That has not happened. In August, executives said there was no broad halo, the sales force was prioritizing ZUSDURI, and clinical trials might be enrolling patients who would otherwise have received JELMYTO.

The numbers have now caught up. Management cut its full-year JELMYTO forecast to about $90 million, from a prior range of $97 million to $101 million. That is below the $94 million it earned in 2025. Last quarter, JELMYTO sales were $21.0 million versus $25.7 million a year earlier, including a one-time $1.5 million charge.

This is not a catastrophe. It does mean the company's second pillar is eroding just as the first one rises.

The second complication: Growth is slowing, as growth does

ZUSDURI grew 73% in the previous quarter and 35% in this one. Percentages naturally fall as the base gets bigger, so dollars are the fairer test.

The drug added roughly $15 million in sales, then $21 million, then $18 million in successive quarters. The latest increment was smaller than the one before. One data point is not a trend, but it is the number for investors to watch.

The market appears to have the same worry. The stock rose to nearly $51 after the prior report, then gave back the entire gain, closing at $34.04 just before this one.

Management also declines to give a full-year ZUSDURI forecast. They said they would let demand trends develop first. That is honest, and also a reminder that the future here is still unknown to the people closest to it.

The third complication: The balance sheet

Management says it has enough money to reach profitability without selling more stock. The reasoning deserves a closer look.

The company ended the quarter with $90.5 million in cash and marketable securities. A quarter earlier it had $108.0 million, against total liabilities of $385 million and a shareholders' deficit of $132 million. Cash fell about $17 million in a quarter when the company nearly broke even.

Management points to $117 million in accounts receivable, which is money customers owe the company for products already delivered. That is more than a full quarter of revenue. It is earned on paper, but it is not cash until collected.

Two questions follow. How quickly do these customers pay? And how much product sits unused in distributors' warehouses, known as channel inventory? Revenue recorded on shipment can run ahead of actual patient use, and later reverse.

The company also carries fixed claims on its future. Interest on its long-term debt was $4.8 million for the quarter, and a financing arrangement with the investment firm RTW added $4.5 million in non-cash expense. In plain terms, the company has partly borrowed against its own success.

The upside case: Why operating leverage matters

Here is the reason to stay interested. Operating leverage means that when costs are mostly fixed, extra revenue falls largely to profit.

Quarterly spending was $26.0 million on research and $47.2 million on selling and administration. That is about $73 million against $89 million in revenue from a product with a very high gross margin (the share of each sale left after the direct cost of making it).

If ZUSDURI keeps adding even $10 million a quarter, most of it lands as profit. Management is spending hard anyway, having raised full-year expense guidance to $260 million to $270 million. That is the right call if demand is durable, and a risk if it is not.

Defending the franchise

UroGen's protections are real. A new patent is expected to cover ZUSDURI and its successor, UGN-103, through July 2044.

UGN-103 is a next-generation version. Management has filed a New Drug Application, or NDA, the formal request for FDA approval. The agency's review deadline, called a PDUFA date (named for the Prescription Drug User Fee Act), is June 14, 2027, according to the company. If approved, it would need its own J-code.

The patent protects the gel, not the market. Larger companies are developing competing treatments in neighboring parts of bladder cancer. Johnson & Johnson currently has a drug-releasing device in late-stage trials for intermediate-risk disease.

What's next?

Investors should read the company's quarterly report to the SEC (the Securities and Exchange Commission, the U.S. securities regulator), called a 10-Q. Look for four things:

• How fast customers pay, and any comment on channel inventory.
• The total debt and when it comes due.
• What the fourth-quarter profit forecast assumes for JELMYTO.
• Whether ZUSDURI's dollar additions bounce back next quarter.

The medicine is real, the launch is real, and patients are plainly being helped. The open question is whether the balance sheet and the share price were built for a launch that is maturing.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.